1. Abstract 527: Myeloid PTEN deficiency impairs tumor immune surveillance via immune checkpoint inhibition
- Author
-
Daniel Kraemmer, Gernot Schabbauer, Alexander M. Dohnal, Andrea Vogel, Robert Eferl, Julia Pisoni, Bastian Hoesel, Klara Soukup, Mario Kuttke, Stephan Blüml, Manuel Salzmann, Leslie Hanzl, José Basílio, Carl-Walter Steiner, Johannes A. Schmid, Emine Sahin, Günther Lametschwandtner, Hannah Paar, Sophie Percig, Julia S. Brunner, Angela Halfmann, and Bernhard Hochreiter
- Subjects
Cancer Research ,Myeloid ,biology ,Melanoma ,Cancer ,Inflammation ,medicine.disease ,Immune checkpoint ,medicine.anatomical_structure ,Cell killing ,Immune system ,Oncology ,Immunology ,medicine ,biology.protein ,PTEN ,medicine.symptom - Abstract
In the current study we are investigating the effects of PTEN-deficient myeloid cells on tumor immune surveillance. We could previously show that hyper-activation of the PI3K signaling cascade by genetic knock-out of the counteracting phosphatase PTEN induced an anti-inflammatory phenotype in myeloid cells. This resulted in protection of conditional knock-out mice in models of acute infection and inflammation. A reduction in pro-inflammatory responses could however increase tumor burden. To address this question we induced colitis associated colon cancer in conditional PTEN-KO mice and found an increase in tumor burden and a reduction in survival in male KO mice. This was accompanied by increased numbers of splenic antigen-presenting cells (APC) expressing the immune checkpoint regulators PD-L1 and PD-L2. Furthermore, transcriptome analysis in these cells revealed a shift towards gene expression profiles found in professional APCs capable of cross-presentation. As expected, ex-vivo stimulated T-cells from KO-mice showed a reduction in proliferative capacity. These findings were further substantiated by findings in a second tumor model using implanted B16 melanoma cells. In this model myeloid PTEN-deficient mice showed a decrease in T-cell activation and a reduction in melanoma cell killing capacity. Taken together, our findings show that genetic deletion of PTEN in cells of myeloid origin increases splenic APCs expressing immune checkpoint regulators resulting in a decrease in tumor immune surveillance. Our study shows that PI3K-inhibitors which are currently tested as anti-cancer drugs might have additional beneficial effects on immune cells by shifting their inflammatory phenotype. Citation Format: Mario Kuttke, Emine Sahin, Julia Pisoni, Sophie Percig, Andrea Vogel, Daniel Kraemmer, Leslie Hanzl, Julia Stefanie Brunner, Hannah Paar, Klara Soukup, Angela Halfmann, Alexander Dohnal, Carl-Walter Steiner, Stephan Blüml, Jose Basilio, Bernhard Hochreiter, Manuel Salzmann, Bastian Hoesel, Günther Lametschwandtner, Robert Eferl, Johannes Schmid, Gernot Schabbauer. Myeloid PTEN deficiency impairs tumor immune surveillance via immune checkpoint inhibition. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 527.
- Published
- 2016